Drug-drug cocrystals, which can regulate physicochemical properties of individual drugs and might produce synergistic therapeutic effects, have drawn growing interest in the pharmaceutical industry. In this study, a novel drug-drug (1:1) cocrystal hydrate of slightly water-soluble dihydromyricetin (DMY) and highly water-soluble pentoxifylline (PTX), DMY-PTX•HO (1), was prepared by a slurry method. The single-crystal X-ray diffraction results reveal that the cocrystal is formed through hydrogen-bonding interactions between hydroxyl groups of DMY and four acceptors of PTX. The dynamic vapour sorption results indicate that the cocrystal displays reduced hydrophilicity compared with DMY. It is found that cocrystal formation narrows the solubility difference between two parent drugs. The equilibrium solubility of PTX decreases greatly, while that of DMY increases slightly. As a result, DMY and PTX are synchronously and sustainedly released from the cocrystal. Further, a synergistic anti-cancer effect of the cocrystal DMY-PTX•HO (1) on HepG2 cells in vitro at a drug concentration of 100 μM was discovered. This study brings evidence of cocrystallization as a successful approach for synchronous sustained-release of two drugs with substantially different aqueous solubility.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.xphs.2021.06.021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-Drug Cocrystal Alloy and Nanoformulation of Cytarabine: Optimized Biopharmaceutical Property and Synergistic Antitumor Efficacy.
Mol Pharm
November 2024
Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science, Qingdao, Shandong 266234, PR China.
Article Synopsis
- An innovative strategy uses cocrystallization and nanotechnology to enhance the effectiveness of the marine antitumor drug cytarabine (ARA) by combining it with uracil (U) and 5-fluorouracil (FU) into a new cocrystal alloy (ARA-FU-U) and converting it into a nanocrystal.
- The cocrystal alloy benefits from a unique hydrogen-bonding system that stabilizes ARA, while both the alloy and nanocrystal forms improve the drug's physical properties and drug absorption for better pharmacokinetics.
- The synergistic antitumor effect of ARA and FU is significantly increased in the cocrystal alloy, suggesting that U helps maintain
Evaluating experimental, knowledge-based and computational cocrystal screening methods to advance drug-drug cocrystal fixed-dose combination development.
Eur J Pharm Sci
December 2024
Department of Chemical Sciences, SSPC the SFI Research Centre for Pharmaceuticals, Bernal Institute, University of Limerick, Limerick, Ireland. Electronic address:
Fixed-dose combinations (FDCs) offer significant advantages to patients and the pharmaceutical industry alike through improved dissolution profiles, synergistic effects and extended patent lifetimes. Identifying whether two active pharmaceutical ingredients have the potential to form a drug-drug cocrystal (DDC) or interact is an essential step in determining the most suitable type of FDC to formulate. The lack of coherent strategies to determine if two active pharmaceutical ingredients that can be co-administered can form a cocrystal, has significantly impacted DDC commercialisation.
View Article and Find Full Text PDFEffects of Polymers on Cocrystal Growth in a Drug-Drug Coamorphous System: Relations between Glass-to-Crystal Growth and Surface-Enhanced Crystal Growth.
Mol Pharm
July 2024
Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Coamorphous and cocrystal drug delivery systems provide attractive crystal engineering strategies for improving the solubilities, dissolution rates, and oral bioavailabilities of poorly water-soluble drugs. Polymeric additives have often been used to inhibit the unwanted crystallization of amorphous drugs. However, the transformation of a coamorphous phase to a cocrystal phase in the presence of polymers has not been fully elucidated.
View Article and Find Full Text PDFEfficient Screening of Pharmaceutical Cocrystals by Microspacing In-Air Sublimation.
J Am Chem Soc
May 2024
State Key Laboratory of Crystal Materials, Institute of Crystal Materials, Shandong University, Jinan 250100, P. R. China.
Cocrystal screening and single-crystal growth remain the primary obstacles in the development of pharmaceutical cocrystals. Here, we present a new approach for cocrystal screening, microspacing in-air sublimation (MAS), to obtain new cocrystals and grow high-quality single crystals of cocrystals within tens of minutes. The method possesses the advantages of strong designable ability of devices, user-friendly control, and compatibility with materials, especially for the thermolabile molecules.
View Article and Find Full Text PDFAn analysis of multidrug multicomponent crystals as tools for drug development.
J Control Release
May 2024
School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK. Electronic address:
In a typical tablet or capsule formulation, the active drug is often present as a crystalline solid. This solid emerges from the relationships between the individual atoms within the crystal, which confer a distinct set of physical properties. Then, it follows that if we modify the packing arrangement of the individual molecules within these crystals, we can modulate their properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!